Abstract:Background: Type 2 diabetes mellitus (T2DM) known as non-insulin-dependent diabetes mellitus, which is increasingly acknowledged as being associated with an increased risk for a series of cancers. Pancreatic cancer is currently the fourth most common cause of cancer-related mortality, which has been proved to be worsened by internal diabetic condition. However, the underlying molecular mechanisms are less addressed. Furthermore, current knowledge revealed that therapeutic strategy by anti-diabetes for pancreatic cancer under diabetes condition have no satisfactory efficacy, and nor by chemotherapy in our study.Methods: To clarify these mysteries and widen our knowledge, both obesity-associated and non-obese-associated T2DM mouse models were generated by chemical induction with streptozotocin (STZ) and leptin receptor knockout (db/db) in mice. Then, the process of tumor progression was researched, and the gene expression profiling of pancreatic cancer in mice was performed using RNA-seq.Results: Our results showed that pancreatic cancer malignancy was increased with notable proliferation and metastatic potential in two diabetic mice model. Totally, 136 and 64 significantly differentially expressed genes (DEGs) were identified in STZ and db/db mice by transcriptomic analysis. The results also suggested that different carcinogenesis-related genes and potential molecular mechanisms contribute to the malignancy of pancreatic cancer in obesity-associated and non-obesity-associated T2DM. In obesity-associated db/db mice, the GO subcategories associated with most of the genes with downregulated expression are involved in the immune response. However, in non-obesity-associated STZ mice, in addition to the immune response category, the enriched subcategories also included angiogenesis and the extracellular matrix. While, two genes respectively encoding MMP-2 and MMP-9 were simultaneously abnormal up-regulated in pancreatic cancer tissue from diabetic mice of both STZ and db/db, that could act as potential therapeutic targets for significantly suppressing the malignant progression. Furthermore, an optimizing therapeutic strategy was further proposed that combining MMP-2/9 inhibitor with gemcitabine significantly enhanced anti-tumor effects on pancreatic cancer under diabetic condition, providing a theoretical basis for clinical applications.Conclusions: Generally, this study provides a comprehensive insight into diabetes as a risk factor for pancreatic cancer and has the potential to guide the development of enhanced treatment strategies.

Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL5

Sorcin-STAT3-Serpin E1/CCL5 Axis Can Be the Trigger of Pancreatic Cancer-Associated New-Onset Diabetes

Sorcin promotes proliferation of hepatocellular carcinoma by regulating VEGFA/B via PI3K pathway

Associations of Diabetes, Circulating Protein Biomarkers, and Risk of Pancreatic Cancer

Type 2 diabetes-associated single nucleotide polymorphism in Sorcs1 gene results in alternative processing of the Sorcs1 protein in INS1 β-cells

Increased serum extrachromosomal circular DNA SORBS1circle level is associated with insulin resistance in patients with newly diagnosed type 2 diabetes mellitus

A Variation in SORBS1 is Associated with Type 2 Diabetes and High‐density Lipoprotein Cholesterol in Chinese Population

Exosomes Derived from Pancreatic Cancer Cells Induce Insulin Resistance in C2C12 Myotube Cells Through the PI3K/Akt/FoxO1 Pathway

New insights into pancreatic cancer-induced paraneoplastic diabetes

Sorcin regulate pyroptosis by interacting with NLRP3 inflammasomes to facilitate the progression of hepatocellular carcinoma

Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer

Altered profile of serum microRNAs in pancreatic cancer associated new-onset diabetes mellitus.

Gene signature for prognosis in comparison of pancreatic cancer patients with diabetes and non-diabetes

Serum metabolomics differentiating pancreatic cancer from new-onset diabetes

Transcriptomic Analyses and Potential Therapeutic Targets of Pancreatic Cancer With Concomitant Diabetes

1652P Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis

Machine learning identifies SLC6A14 as a novel biomarker promoting the proliferation and metastasis of pancreatic cancer via Wnt/β-catenin signaling

Clinical Significance and Prognostic Value of Human Soluble Resistance-Related Calcium-Binding Protein: A Pan-Cancer Analysis

Pancreatic Cancer-Derived Exosomes Suppress the Production of GIP and GLP-1 from STC-1 Cells in Vitro by Down-Regulating the PCSK1/3

Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles.

Expression and Clinical Implications of the Soluble Drug Resistance-Related Calcium-Binding Protein (sorcin) Gene in Leukemia Patients.